The World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19.
WHAT MAKES COVAXIN DIFFERENT?
Covaxin is manufactured differently from Pfizer BioNTech and Moderna vaccines. Pfizer and Moderna are mRNA vaccines, a relatively new approach that teaches our cells to produce proteins that trigger immune responses in our bodies.
Covaxin takes a more traditional approach. It is made using a deactivated form of the COVID-19 virus to stimulate the immune system. This is similar to Johnson & Johnson’s approach to vaccines.
Mr. Bagchi said :
“96 countries have accepted WHO-approved vaccines or have recognized our vaccines. In a significant development, India developed and produced Covaxin was accorded the emergency use licensing by World Health Organization (WHO) earlier this month on November 3. This should ease the international travel of those vaccinated with Covaxin. Many countries already recognize WHO-approved vaccines and now with Covaxin joining this list that should become automatic. “
